In conclusion, SPP1 might be an important regulator of tumor immune cell infiltration and act as a promising prognostic biomarker for ovarian cancer patients, offering a new probable immunotherapeutic target in ovarian cancer. This evidence concerns the gene SPP1 and ovarian carcinoma.